TGFB1 and chronic kidney disease: In contrast to VEGF, agents that target the pro-sclerotic factor TGF-β, either directly [29] or indirectly [28], have been shown to attenuate not only fibrosis and declining kidney function, but to also reduce proteinuria in models of CKD.